The sensitivity of GNAS and KRAS mutations for identifying IPMN with a higher risk of malignancy (surgical cohort) is relatively low, at 32.0% and 16.0%, respectively. Here, GNAS is linked to pancreatic intraductal papillary-mucinous neoplasm.